### Supplementary Table 1. Influence of the density of tumour-infiltrating immune cell types on the prognosis of patients with cancer (FIGS 2 and 3)

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Impact of CD8+ T cells References</th>
<th>Patient No. (CD8)</th>
<th>Impact of TLSs References</th>
<th>Patient No. (TLS)</th>
<th>Impact of Tregs References</th>
<th>Patient No. (Tregs)</th>
<th>Impact of macroph. References</th>
<th>Patient No. (Macro)</th>
<th>Impact of M1 References</th>
<th>Patient No. (M1)</th>
<th>Impact of M2 References</th>
<th>Patient No. (M2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast cancer</strong></td>
<td>Good 1, 2, 3, 4, 5, 6, 7, 8, 9, 10</td>
<td>N=3868</td>
<td>Good 11, 12, 13, 14</td>
<td>N=1533</td>
<td>None 15</td>
<td>Poor 19, 7, 20, 21, 22, 23</td>
<td>Poor 4143</td>
<td>Poor 23</td>
<td>Poor N=144</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pancreatic cancer</strong></td>
<td>Good 24, 25</td>
<td>N=252</td>
<td>Good 27</td>
<td>N=534</td>
<td>Poor 28</td>
<td>Poor 29</td>
<td>Good 40, 38</td>
<td>Good N=232</td>
<td>Poor N=434</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastric cancer</strong></td>
<td>Good 34, 35</td>
<td>N=50</td>
<td>Good 36</td>
<td>Good N=82</td>
<td>Good 34, 35</td>
<td>Good N=148</td>
<td>Poor 39, 40</td>
<td>Poor N=215</td>
<td>Poor N=434</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Melanoma</strong></td>
<td>Good 42</td>
<td>N=152</td>
<td>Good 43, 44</td>
<td>Good N=103</td>
<td>None 45, 46</td>
<td>Poor 47, 48</td>
<td>Poor 49</td>
<td>Poor N=227</td>
<td>Poor N=227</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Colorectal cancer</strong></td>
<td>Good 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63</td>
<td>N=4731</td>
<td>Good 64, 65, 66, 67, 68</td>
<td>Good N=563</td>
<td>Good 51, 69, 70, 71</td>
<td>Good N=2660</td>
<td>Good 72, 73, 74, 75, 76</td>
<td>Good N=1098</td>
<td>Poor N=289</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lung carcinoma</strong></td>
<td>Good 78, 79, 80</td>
<td>N=355</td>
<td>Good 83, 84</td>
<td>Good N=558</td>
<td>Poor 85, 86, 87, 88, 89</td>
<td>Poor 719</td>
<td>Good 79, 90, 91</td>
<td>Good N=414</td>
<td>Poor N=140</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Head and neck cancers</strong></td>
<td>Good 98, 99, 100, 101, 102, 103, 104, 105, 106, 107</td>
<td>N=1031</td>
<td>Good 108</td>
<td>Good N=80</td>
<td>Good 109, 110</td>
<td>None 111</td>
<td>Good 93, 94</td>
<td>Good N=140</td>
<td>None N=435</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poor 107</td>
<td>Poor N=43</td>
<td>None 111</td>
<td>Poor 112, 106</td>
<td>None 110</td>
<td>None 60</td>
<td>Poor 95</td>
<td>Poor N=378</td>
<td>Poor N=378</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour Type</td>
<td>Good References</td>
<td>Poor References</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>116, 117, 118, 119</td>
<td>None, 120, 121, 119, 122, 123, 124, 125</td>
<td>N=669, 120, N=438, N=141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>132, 133, 134, 135, 136, 137</td>
<td>Good References, 138, None, N=758</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>143, None, N=325</td>
<td>Poor References, N=144, N=535</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>147, 148, 149, 380</td>
<td>Good References, 150, N=37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oesophageal cancer</td>
<td>155, 156, None, N=122, N=103</td>
<td>None, 159, N=70, Poor References, N=160, 159, 158</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glioma</td>
<td>None, N=163, 164</td>
<td>None, N=164, 165, 166, 167, 163, 168, N=152</td>
<td>N=289, N=91, Poor References, N=172, N=100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal cell cancer</td>
<td>Poor References, N=170, 171, N=356</td>
<td>Good References, 172, N=562</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biliary Tract cancer</td>
<td>Good References, 175, 176, 177, 178, 179, 180</td>
<td>Poor References, N=173, N=185, N=329</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merkel cell carcinoma</td>
<td>Good References, 178, 179, 180, N=234</td>
<td>None, N=263</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid Cancer</td>
<td>Good References, 181</td>
<td>None, N=182, N=141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant peripheric nerve sheath tumor</td>
<td>None, None, N=32</td>
<td>Good References, N=32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung cancer brain metastasis</td>
<td>Good References, 183, N=32</td>
<td>None, N=141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Good</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma brain metastases</td>
<td>184</td>
<td>N=40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer liver metastasis</td>
<td>185</td>
<td>N=234</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer lung metastasis</td>
<td>64</td>
<td>N=140</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal cell cancer lung metastasis</td>
<td>Poor 64</td>
<td>N=52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References to Supplemental Table 1:


60 Nagtegaal, I. D. et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect—a histopathological and immunohistochemical study. BMC cancer 1, 7 (2001).


123 Tu, J. F. et al. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Scientific reports 6, 35056, doi:10.1038/srep35056 (2016).


SUPPLEMENTARY INFORMATION


153 Sjodahl, G. et al. Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urologic oncology 32, 791-797, doi:10.1016/j.urolonc.2014.02.007 (2014).


